[Growth hormone (GH) deficiency treatment in children: comparison between uses of pen versus bottles/syringes on GH administration]
- PMID: 18157384
- DOI: 10.1590/s0004-27302007000700011
[Growth hormone (GH) deficiency treatment in children: comparison between uses of pen versus bottles/syringes on GH administration]
Abstract
The aim of this study was to compare two preparations of recombinant human GH (rGH) in the treatment of GH deficient patients. Ten prepubertal GH-deficient children were followed during 6 months. They received injections with syringe for 3 months, followed by pen administration for the subsequent 3 months. Acceptability was evaluated through a questionnaire. Waste of medication was calculated by the difference between the number of used bottles or refills and the calculated amount for the period. Treatment response was evaluated by SDS gain of height measured each 3 months. After 6 months, 90% of patients/family members declared they preferred the pen regarding technical facility and local pain, and all patients considered the pen easier to transport and store. The waste of medication was lower with pen administration, as was the final cost. We concluded that pen-administered rGH treatment is more convenient, better accepted by the patients, and leads to less waste of medication when compared to the syringe administration.
Similar articles
-
Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.Clin Ther. 2009 Dec;31(12):2906-14. doi: 10.1016/j.clinthera.2009.12.014. Clin Ther. 2009. PMID: 20110030
-
Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD).J Clin Endocrinol Metab. 2012 Feb;97(2):400-7. doi: 10.1210/jc.2011-2234. Epub 2011 Dec 7. J Clin Endocrinol Metab. 2012. PMID: 22162481 Clinical Trial.
-
Growth hormone therapy with a new delivery system.Indian J Pediatr. 1991 Sep-Oct;58 Suppl 1:43-50. doi: 10.1007/BF02750982. Indian J Pediatr. 1991. PMID: 1824374 Clinical Trial.
-
Status of long-acting-growth hormone preparations--2015.Growth Horm IGF Res. 2015 Oct;25(5):201-6. doi: 10.1016/j.ghir.2015.07.004. Epub 2015 Jul 14. Growth Horm IGF Res. 2015. PMID: 26187188 Review.
-
Growth hormone therapy: emerging dilemmas.Pediatr Endocrinol Rev. 2011 Jun;8(4):364-73. Pediatr Endocrinol Rev. 2011. PMID: 21972776 Review.
Cited by
-
Non-pharmacological management of infant and young child procedural pain.Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD006275. doi: 10.1002/14651858.CD006275.pub4. Cochrane Database Syst Rev. 2023. PMID: 37314064 Free PMC article.
-
Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.Ital J Pediatr. 2018 Sep 27;44(1):113. doi: 10.1186/s13052-018-0548-z. Ital J Pediatr. 2018. PMID: 30261918 Free PMC article.
-
Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device.J Endocrinol Invest. 2016 Dec;39(12):1419-1424. doi: 10.1007/s40618-016-0510-0. Epub 2016 Jul 12. J Endocrinol Invest. 2016. PMID: 27406716 Free PMC article.
-
Non-pharmacological management of infant and young child procedural pain.Cochrane Database Syst Rev. 2015 Dec 2;2015(12):CD006275. doi: 10.1002/14651858.CD006275.pub3. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Jun 14;6:CD006275. doi: 10.1002/14651858.CD006275.pub4. PMID: 26630545 Free PMC article. Updated.
-
Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.BMC Endocr Disord. 2011 Feb 4;11:4. doi: 10.1186/1472-6823-11-4. BMC Endocr Disord. 2011. PMID: 21294891 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical